Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Breast Cancer
- Frequent Receptor Conversion in Distant Breast Cancer Metastases
- Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations in Metastatic Triple-Negative Breast Cancer
- Personal History of Proliferative Breast Disease With Atypia and Risk of Multifocal Breast Cancer
- Long-Term Outcomes for Neoadjuvant vs Adjuvant Chemotherapy in Early Breast Cancer
- 2017 Top Stories in Oncology: CAR-T Cell Therapies
- Sorafenib Compared With Capecitabine vs Placebo With Capecitabine in Advanced HER2− Breast Cancer
- Radiation and Immunotherapy: Novel Concepts From SABCS 2017
- New Modalities for Genomic Profiling of HER2+ Breast Cancer From SABCS 2017
- New Data on Androgen Receptor Blockade in Breast Cancer: A Review From SABCS 2017